Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

42.86
Delayed Data
As of 9:27am ET
 +0.88 / +2.07%
Today’s Change
36.71
Today|||52-Week Range
44.85
+7.74%
Year-to-Date
Better Buy: GlaxoSmithKline plc vs. Merck
8:23am / MotleyFool.com - Paid Partner Content
Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals
Jun 28 / MotleyFool.com - Paid Partner Content
'Shark Tank's' Kevin O'Leary Finds 'The Opportunity of a Lifetime'
Jun 30 / TheStreet.com - Paid Partner Content
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Jun 27 / MotleyFool.com - Paid Partner Content
These 3 Biotechs Are Down More Than 36% This Year, and They're Bargains
Jun 29 / MotleyFool.com - Paid Partner Content
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
New Stock Research Reports for June 28, 2016
Jun 28 / Zacks.com - Paid Partner Content
How Does Brexit Impact Healthcare Stocks?
Jun 27 / Zacks.com - Paid Partner Content
Shire and Glaxo Offer Prescription to London's Woes
Jun 28 / TheStreet.com - Paid Partner Content
GlaxoSmithKline (GSK) Flagged As Today's Pre-Market Laggard
Jun 27 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close42.46
Today’s open42.52
Day’s range42.45 - 43.34
Volume4,657,715
Average volume (3 months)3,491,392
Market cap$105.6B
Dividend yield5.45%
Data as of 9:27am ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)+181.82%
Earnings growth (this year)+14.03%
Earnings growth (next 5 years)+8.20%
Revenue growth (last year)-3.66%
P/E ratio185.2
Price/Sales2.70
Price/Book13.91

Competitors

 Today’s
change
Today’s
% change
NVONovo Nordisk+0.77+1.45%
ABBVAbbVie+0.10+0.16%
SNYSanofi+0.59+1.43%
AGNAllergan+0.54+0.23%
Data as of 06/30/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)$0.60
Annual revenue (last year)$36.5B
Annual profit (last year)$12.8B
Net profit margin35.20%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Andrew Philip Witty
Chief Financial Officer &
Executive Director
Simon Dingemans
Corporate headquarters
Brentford, Greater London

Forecasts

Partner Offers

Search for Jobs